Severe acute respiratory syndrome coronavirus 2 vaccination in children with a history of multisystem inflammatory syndrome in children: an international survey

Author(s):
Hoste, L.; Soriano-Arandes, A.; Buddingh, E.P. (0000-0002-2755-9408); Whittaker, E.; Belot, A.; Ulloa-Gutierrez, R.; Olbrich, P.; Haerynck, F.; MIS-C Researchers
Published
2022
Publication type
Article / Letter to editor

Abstract

The optimal severe acute respiratory syndrome coronavirus 2 vaccine strategy for patients with a history of multisystem inflammatory syndrome in children (MIS-C) is unclear. We performed an international survey (32 countries) and found substantial variations in vaccine policies. Respondents did not report relapses of MIS-C or other severe inflammatory side effects after severe acute respiratory syndrome coronavirus 2 vaccination in 273 patients with a history of MIS-C. (J Pediatr 2022;248:114-8).

Date issued
2022-09-01
Language
English
Publisher
MOSBY-ELSEVIER
Is part of
The Journal of Pediatrics (2022), Vol. 248, p. 114-118
hdl
1887/3575929
doi
10.1016/j.jpeds.2022.05.028
URL
https://www.sciencedirect.com/science/article/pii/S0022347622004383?via%3Dihub